Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe, Chronic Plaque-Type Psoriasis

Inclusion Criteria:

• Subjects with chronic, plaque-type psoriasis for at least 6 months
• Must have moderate to severe psoriasis based on PASI greater than 12, IGA greater than 3, and greater than 10% body surface area
• Must be inadequately controlled by prior treatments (topicals, phototherapy, and/orsystemic therapies)

Exclusion Criteria:

• Forms of psoriasis other than chronic, plaque-type (such as pustular, erythrodermicand guttate psoriasis)
• Drug induced psoriasis
• Use of other psoriasis treatments during the study
• Prior use of etanercept
• Prior use of secukinumab or any other drug that target IL-17 (interleukin 17) or theIL-17 receptor
• Pregnant or lactating women; women who do not agree to use contraception during thestudy and for 16 weeks after stopping treatment
• Significant medical problems such as uncontrolled high blood pressure, congestiveheart failure, etc.
• History of an ongoing, chronic or recurrent infection or evidence of tuberculosis
• Allergy to rubber or latex Other protocol-defined inclusion/exclusion criteria may apply